Harbour BioMed and BioMap Launch MegaStream TechBio for AI Based Biologics Research

June 16, 2026
Harbour BioMed and BioMap have formed a strategic partnership to create MegaStream TechBio, an AI based drug development platform focused on complex biologics across multiple therapeutic areas.

Harbour BioMed and BioMap announced in a press release the launch of MegaStream TechBio, a new company focused on AI based discovery and development of complex biologics. The initiative combines Harbour BioMed's antibody technology and clinical expertise with BioMap's life science foundation models and AI infrastructure.

MegaStream will integrate proprietary datasets, large models, and an extensive biologics pipeline into a unified research and development engine. The platform includes an intelligent dry and wet laboratory designed for automated validation, data accumulation, and model iteration across the drug discovery cycle.

The collaboration aims to accelerate the creation of first in class and best in class therapeutic assets in cardiovascular, renal, oncology, and anti aging fields. Harbour BioMed contributes its fully human antibody platform and target biology expertise, while BioMap provides its xTrimo life science models and generative AI technology.

MegaStream’s initial projects will include AI identified drug candidates from earlier joint work and new discovery programs. The company plans to advance hundreds of biologic programs in parallel, supported by a management team drawn from both the biopharmaceutical and AI sectors.

We hope you enjoyed this article.

Consider subscribing to one of our newsletters like Enterprise AI Brief, Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Enterprise AI Healthcare & Life Sciences AI AI Brief AI Brief (X)

More from: Enterprise

06/16
Trust3 AI Introduces AgentDOS for Enterprise AI Agent Observability
06/16
APRIL Launches Motorcycle Insurance App in ChatGPT
06/16
HaystackID Introduces COMET Compliance Oversight Solution at LegalTechTalk 2026
06/16
TELUS Digital Partners with Cresta to Deploy AI Agents for Customer Experience
06/16
DigitalXForce Launches Enterprise TRiSCM Platform for AI and Quantum Risk Management

More from: Life Sciences

06/16
CCRM, OmniaBio, and Avectas Partner to Advance Cell Therapy Manufacturing
06/16
DeepIntent Launches Helix AI for Healthcare Marketing Insights
06/16
Toboggan Labs Joins Mila’s Partner Network to Advance Healthcare AI
06/16
IDBS and Alchemi Partner to Automate Biopharma Regulatory Filings with AI Agents
06/16
cliexa and OpiSafe Partner on AI Platform for Opioid Stewardship and Behavioral Health

Subscribe to Enterprise AI Brief

Weekly report on AI business applications, enterprise software releases, automation tools, and industry implementations.

AI Token Webinar

Industry analysis

2025 Global Business Services Agenda: Gen AI Takes Center Stage

The Hackett Group

This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.

Read more

You May Also Like